2024
Meningeal lymphatic vessel dysfunction driven by CGRP signaling causes migraine-like pain in mice
Thomas J, Schindler E, Gottschalk C. Meningeal lymphatic vessel dysfunction driven by CGRP signaling causes migraine-like pain in mice. Journal Of Clinical Investigation 2024, 134: e182556. PMID: 39087472, PMCID: PMC11290958, DOI: 10.1172/jci182556.Peer-Reviewed Original ResearchConceptsBlocking CGRP signalingCGRP receptor componentsMigraine-like painCervical lymph nodesGap junction proteinPrimary headache disordersLymphatic vessel dysfunctionAcute migrainePharmacological blockadeLymph nodesHeadache disordersNeurological symptomsJunction proteinsCGRPLymphatic vesselsMeningeal lymphatic vesselsInducible knockoutVessel dysfunctionMigraineReceptor componentsHeadachePainPathophysiologyDysfunctionMicePsychotropic Drugs Reemerging as Headache Medicines
Schindler E. Psychotropic Drugs Reemerging as Headache Medicines. CNS Drugs 2024, 1-10. PMID: 39037675, DOI: 10.1007/s40263-024-01107-x.Peer-Reviewed Original Research
2023
Studying classic psychedelics for the management of headache disorders: Considerations for Veterans
Schindler E, Sico J. Studying classic psychedelics for the management of headache disorders: Considerations for Veterans. Journal Of Military Veteran And Family Health 2023, 9: 88-95. DOI: 10.3138/jmvfh-2023-0006.Peer-Reviewed Original ResearchHeadache disordersCluster headacheLysergic acid diethylamideTreatment optionsBrain injuryTherapeutic effectAcid diethylamideTraumatic brain injuryConventional treatment optionsTrials of psilocybinMilitary membersPoor qualityPsychedelic drugsSummary PatientsHead traumaAvailable treatmentsHeadache managementHeadache treatmentCommon conditionHigh riskSide effectsSignificant disabilityHeadacheMore researchPoor efficacyAdapting psychedelic medicine for headache and chronic pain disorders
Schindler E, Hendricks P. Adapting psychedelic medicine for headache and chronic pain disorders. Expert Review Of Neurotherapeutics 2023, 23: 867-882. PMID: 37652000, DOI: 10.1080/14737175.2023.2246655.Peer-Reviewed Original ResearchConceptsChronic pain disordersPain disordersHeadache disordersChronic pain patientsRecent case reportsDifferent treatment paradigmsPsychedelic medicineSubstance use disordersMechanism of actionPain patientsChronic painCase reportClinical trialsTreatment paradigmTreatment outcomesTherapeutic effectLarge dosesUse disordersAdjunctive psychotherapyTherapeutic outcomesHeadacheBeneficial effectsSubjective effectsBranches of medicineDisordersThe Potential of Psychedelics for the Treatment of Episodic Migraine
Schindler E. The Potential of Psychedelics for the Treatment of Episodic Migraine. Current Pain And Headache Reports 2023, 27: 489-495. PMID: 37540398, DOI: 10.1007/s11916-023-01145-y.Peer-Reviewed Original ResearchConceptsEpisodic migrainePotential of psychedelicsWeekly migraine daysPsychedelic drugsMigraine daysPain intensityTransitional treatmentCluster headacheHeadache disordersPreventive effectClinical trialsSingle administrationTherapeutic effectAbortive effectMigrainePsychiatric conditionsReviewThis reviewTherapeutic agentsDrugsAdditional findingsMedicinal usePsychedelicsTreatmentPotential medicinal usePsilocybin
2022
Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial
Schindler E, Sewell R, Gottschalk C, Luddy C, Flynn L, Zhu Y, Lindsey H, Pittman B, Cozzi N, D'Souza D. Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial. Headache The Journal Of Head And Face Pain 2022, 62: 1383-1394. PMID: 36416492, DOI: 10.1111/head.14420.Peer-Reviewed Original ResearchConceptsAttacks/weekPulse regimenCluster headachePsychotropic effectsAttack frequencyPlacebo-controlled studyPlacebo-controlled trialSerious adverse eventsEffects of psilocybinEffect sizeChronic participantsEfficacy outcomesAdverse eventsModerate effect sizeHeadache burdenHeadache disordersTherapeutic effectHeadache diaryPsilocybin administrationDrug sessionsExperimental drugsRegimenPsilocybin-containing mushroomsDefinitive studiesFinal analysisRecent advances in the diagnosis and management of cluster headache
Schindler EAD, Burish MJ. Recent advances in the diagnosis and management of cluster headache. The BMJ 2022, 376: e059577. PMID: 35296510, DOI: 10.1136/bmj-2020-059577.Peer-Reviewed Original ResearchConceptsCluster headacheHeadache disordersIpsilateral autonomic featuresChronic cluster headacheEpisodic cluster headachePrimary headache disordersFacial painDiagnostic delayTrigeminal neuralgiaSecondary causesTherapeutic featuresEffective treatmentUnilateral attacksHeadacheProper diagnosisNew treatmentsSuicidal ideationAutonomic featuresPainful human experiencesDisordersDiagnosisHigh rateRecent updatesTreatmentRecent advances
2021
Cluster Headache: Clinical Characteristics and Opportunities to Enhance Quality of Life
Grinberg AS, Best RD, Min KM, Schindler EAD, Koo BB, Sico JJ, Seng EK. Cluster Headache: Clinical Characteristics and Opportunities to Enhance Quality of Life. Current Pain And Headache Reports 2021, 25: 65. PMID: 34668084, DOI: 10.1007/s11916-021-00979-8.Peer-Reviewed Original ResearchConceptsQuality of lifeCluster headacheCommon psychiatric comorbiditiesCurrent clinical carePsychological treatmentPrimary headache disordersRecent FindingsPeopleClinical characteristicsSevere painPsychiatric comorbidityDisease burdenHeadache disordersClinical careDepressive symptomsGeneral populationHeadacheSuicidal ideationAutonomic featuresBehavioral interventionsCommitment TherapyPsychological factorsTreatmentBurdenComorbiditiesPainDemoralization predicts suicidality in patients with cluster headache
Koo BB, Bayoumi A, Albanna A, Abusuliman M, Burrone L, Sico JJ, Schindler EAD. Demoralization predicts suicidality in patients with cluster headache. The Journal Of Headache And Pain 2021, 22: 28. PMID: 33879041, PMCID: PMC8056539, DOI: 10.1186/s10194-021-01241-7.Peer-Reviewed Original ResearchConceptsLifetime suicidal ideationSuicidal ideationHigh suicide riskSuicide riskControl participantsDiagnostic criteriaBrief Lifetime Depression ScaleObservational case-control studyLifetime depression historyColumbia-Suicide Severity Rating ScaleCluster headache patientsCase-control studyEdition diagnostic criteriaActive suicidal ideationStepwise logistic regressionSeverity Rating ScaleCH sufferersLittle empiric dataOrbital painCH diagnosisCluster headacheHeadache patientsHeadache disordersDepression ScaleSuicidal Behaviors Questionnaire
2020
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D'Souza D. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics 2020, 18: 534-543. PMID: 33184743, PMCID: PMC8116458, DOI: 10.1007/s13311-020-00962-y.Peer-Reviewed Original ResearchConceptsTherapeutic effectAdverse eventsSingle administrationPsychotropic effectsWeekly migraine daysSerious adverse eventsCross-over studyEffects of psilocybinOral placeboMigraine daysMigraine frequencyClinical effectsControlled StudyHeadache disordersMigraine headacheHeadache diaryDrug effectsDrug AdministrationNeuropsychiatric conditionsMigraineFinal analysisStudy proceduresReceptor ligandsWeeksAdministration
2018
Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics
Schindler EAD, Wallace RM, Sloshower JA, D’Souza D. Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics. Frontiers In Pharmacology 2018, 9: 177. PMID: 29545753, PMCID: PMC5838010, DOI: 10.3389/fphar.2018.00177.Peer-Reviewed Original ResearchCluster headacheClassic serotonergic psychedelicsPersistent therapeutic effectEffects of psychedelicsPotential long-term effectsPsychedelic drugsSystem involvementHeadache disordersTherapeutic resultsPsychedelic-assisted therapyDrug classesTherapeutic effectLong-term effectsMood disordersTherapeutic benefitMethodologic considerationsNeuropsychiatric disordersNeuroendocrine systemPsychedelic effectsHeadacheBeneficial effectsSerotonergic psychedelicsDisordersDrugsRecent reports